Cargando…

Analysis of DNM3 and VAMP4 as genetic modifiers of LRRK2 Parkinson’s disease

The LRRK2 gene has rare (p.G2019S) and common risk variants for Parkinson’s disease (PD). DNM3 has previously been reported as a genetic modifier of the age at onset in PD patients carrying the LRRK2 p.G2019S mutation. We analyzed this effect in a new cohort of LRRK2 p.G2019S heterozygotes (n = 724)...

Descripción completa

Detalles Bibliográficos
Autores principales: Brown, Emmeline E., Blauwendraat, Cornelis, Trinh, Joanne, Rizig, Mie, Nalls, Mike A., Leveille, Etienne, Ruskey, Jennifer A., Jonvik, Hallgeir, Tan, Manuela M.X., Bandres-Ciga, Sara, Hassin-Baer, Sharon, Brockmann, Kathrin, Infante, Jon, Tolosa, Eduardo, Ezquerra, Mario, Ben Romdhan, Sawssan, Benmahdjoub, Mustapha, Arezki, Mohamed, Mhiri, Chokri, Hardy, John, Singleton, Andrew B., Alcalay, Roy N., Gasser, Thomas, Grosset, Donald G., Williams, Nigel M., Pittman, Alan, Gan-Or, Ziv, Fernandez-Santiago, Ruben, Brice, Alexis, Lesage, Suzanne, Farrer, Matthew, Wood, Nicholas, Morris, Huw R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7762821/
https://www.ncbi.nlm.nih.gov/pubmed/32873436
http://dx.doi.org/10.1016/j.neurobiolaging.2020.07.002
_version_ 1783627890390204416
author Brown, Emmeline E.
Blauwendraat, Cornelis
Trinh, Joanne
Rizig, Mie
Nalls, Mike A.
Leveille, Etienne
Ruskey, Jennifer A.
Jonvik, Hallgeir
Tan, Manuela M.X.
Bandres-Ciga, Sara
Hassin-Baer, Sharon
Brockmann, Kathrin
Infante, Jon
Tolosa, Eduardo
Ezquerra, Mario
Ben Romdhan, Sawssan
Benmahdjoub, Mustapha
Arezki, Mohamed
Mhiri, Chokri
Hardy, John
Singleton, Andrew B.
Alcalay, Roy N.
Gasser, Thomas
Grosset, Donald G.
Williams, Nigel M.
Pittman, Alan
Gan-Or, Ziv
Fernandez-Santiago, Ruben
Brice, Alexis
Lesage, Suzanne
Farrer, Matthew
Wood, Nicholas
Morris, Huw R.
author_facet Brown, Emmeline E.
Blauwendraat, Cornelis
Trinh, Joanne
Rizig, Mie
Nalls, Mike A.
Leveille, Etienne
Ruskey, Jennifer A.
Jonvik, Hallgeir
Tan, Manuela M.X.
Bandres-Ciga, Sara
Hassin-Baer, Sharon
Brockmann, Kathrin
Infante, Jon
Tolosa, Eduardo
Ezquerra, Mario
Ben Romdhan, Sawssan
Benmahdjoub, Mustapha
Arezki, Mohamed
Mhiri, Chokri
Hardy, John
Singleton, Andrew B.
Alcalay, Roy N.
Gasser, Thomas
Grosset, Donald G.
Williams, Nigel M.
Pittman, Alan
Gan-Or, Ziv
Fernandez-Santiago, Ruben
Brice, Alexis
Lesage, Suzanne
Farrer, Matthew
Wood, Nicholas
Morris, Huw R.
author_sort Brown, Emmeline E.
collection PubMed
description The LRRK2 gene has rare (p.G2019S) and common risk variants for Parkinson’s disease (PD). DNM3 has previously been reported as a genetic modifier of the age at onset in PD patients carrying the LRRK2 p.G2019S mutation. We analyzed this effect in a new cohort of LRRK2 p.G2019S heterozygotes (n = 724) and meta-analyzed our data with previously published data (n = 754). VAMP4 is in close proximity to DNM3, and was associated with PD in a recent study, so it is possible that variants in this gene may be important. We also analyzed the effect of VAMP4 rs11578699 on LRRK2 penetrance. Our analysis of DNM3 in previously unpublished data does not show an effect on age at onset in LRRK2 p.G2019S carriers; however, the inter-study heterogeneity may indicate ethnic or population-specific effects of DNM3. There was no evidence for linkage disequilibrium between DNM3 and VAMP4. Analysis of sporadic patients stratified by the risk variant LRRK2 rs10878226 indicates a possible interaction between common variation in LRRK2 and VAMP4 in disease risk.
format Online
Article
Text
id pubmed-7762821
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-77628212021-01-01 Analysis of DNM3 and VAMP4 as genetic modifiers of LRRK2 Parkinson’s disease Brown, Emmeline E. Blauwendraat, Cornelis Trinh, Joanne Rizig, Mie Nalls, Mike A. Leveille, Etienne Ruskey, Jennifer A. Jonvik, Hallgeir Tan, Manuela M.X. Bandres-Ciga, Sara Hassin-Baer, Sharon Brockmann, Kathrin Infante, Jon Tolosa, Eduardo Ezquerra, Mario Ben Romdhan, Sawssan Benmahdjoub, Mustapha Arezki, Mohamed Mhiri, Chokri Hardy, John Singleton, Andrew B. Alcalay, Roy N. Gasser, Thomas Grosset, Donald G. Williams, Nigel M. Pittman, Alan Gan-Or, Ziv Fernandez-Santiago, Ruben Brice, Alexis Lesage, Suzanne Farrer, Matthew Wood, Nicholas Morris, Huw R. Neurobiol Aging Genetic Reports Abstract The LRRK2 gene has rare (p.G2019S) and common risk variants for Parkinson’s disease (PD). DNM3 has previously been reported as a genetic modifier of the age at onset in PD patients carrying the LRRK2 p.G2019S mutation. We analyzed this effect in a new cohort of LRRK2 p.G2019S heterozygotes (n = 724) and meta-analyzed our data with previously published data (n = 754). VAMP4 is in close proximity to DNM3, and was associated with PD in a recent study, so it is possible that variants in this gene may be important. We also analyzed the effect of VAMP4 rs11578699 on LRRK2 penetrance. Our analysis of DNM3 in previously unpublished data does not show an effect on age at onset in LRRK2 p.G2019S carriers; however, the inter-study heterogeneity may indicate ethnic or population-specific effects of DNM3. There was no evidence for linkage disequilibrium between DNM3 and VAMP4. Analysis of sporadic patients stratified by the risk variant LRRK2 rs10878226 indicates a possible interaction between common variation in LRRK2 and VAMP4 in disease risk. Elsevier 2021-01 /pmc/articles/PMC7762821/ /pubmed/32873436 http://dx.doi.org/10.1016/j.neurobiolaging.2020.07.002 Text en © 2020 The Authors http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Genetic Reports Abstract
Brown, Emmeline E.
Blauwendraat, Cornelis
Trinh, Joanne
Rizig, Mie
Nalls, Mike A.
Leveille, Etienne
Ruskey, Jennifer A.
Jonvik, Hallgeir
Tan, Manuela M.X.
Bandres-Ciga, Sara
Hassin-Baer, Sharon
Brockmann, Kathrin
Infante, Jon
Tolosa, Eduardo
Ezquerra, Mario
Ben Romdhan, Sawssan
Benmahdjoub, Mustapha
Arezki, Mohamed
Mhiri, Chokri
Hardy, John
Singleton, Andrew B.
Alcalay, Roy N.
Gasser, Thomas
Grosset, Donald G.
Williams, Nigel M.
Pittman, Alan
Gan-Or, Ziv
Fernandez-Santiago, Ruben
Brice, Alexis
Lesage, Suzanne
Farrer, Matthew
Wood, Nicholas
Morris, Huw R.
Analysis of DNM3 and VAMP4 as genetic modifiers of LRRK2 Parkinson’s disease
title Analysis of DNM3 and VAMP4 as genetic modifiers of LRRK2 Parkinson’s disease
title_full Analysis of DNM3 and VAMP4 as genetic modifiers of LRRK2 Parkinson’s disease
title_fullStr Analysis of DNM3 and VAMP4 as genetic modifiers of LRRK2 Parkinson’s disease
title_full_unstemmed Analysis of DNM3 and VAMP4 as genetic modifiers of LRRK2 Parkinson’s disease
title_short Analysis of DNM3 and VAMP4 as genetic modifiers of LRRK2 Parkinson’s disease
title_sort analysis of dnm3 and vamp4 as genetic modifiers of lrrk2 parkinson’s disease
topic Genetic Reports Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7762821/
https://www.ncbi.nlm.nih.gov/pubmed/32873436
http://dx.doi.org/10.1016/j.neurobiolaging.2020.07.002
work_keys_str_mv AT brownemmelinee analysisofdnm3andvamp4asgeneticmodifiersoflrrk2parkinsonsdisease
AT blauwendraatcornelis analysisofdnm3andvamp4asgeneticmodifiersoflrrk2parkinsonsdisease
AT trinhjoanne analysisofdnm3andvamp4asgeneticmodifiersoflrrk2parkinsonsdisease
AT rizigmie analysisofdnm3andvamp4asgeneticmodifiersoflrrk2parkinsonsdisease
AT nallsmikea analysisofdnm3andvamp4asgeneticmodifiersoflrrk2parkinsonsdisease
AT leveilleetienne analysisofdnm3andvamp4asgeneticmodifiersoflrrk2parkinsonsdisease
AT ruskeyjennifera analysisofdnm3andvamp4asgeneticmodifiersoflrrk2parkinsonsdisease
AT jonvikhallgeir analysisofdnm3andvamp4asgeneticmodifiersoflrrk2parkinsonsdisease
AT tanmanuelamx analysisofdnm3andvamp4asgeneticmodifiersoflrrk2parkinsonsdisease
AT bandrescigasara analysisofdnm3andvamp4asgeneticmodifiersoflrrk2parkinsonsdisease
AT hassinbaersharon analysisofdnm3andvamp4asgeneticmodifiersoflrrk2parkinsonsdisease
AT brockmannkathrin analysisofdnm3andvamp4asgeneticmodifiersoflrrk2parkinsonsdisease
AT infantejon analysisofdnm3andvamp4asgeneticmodifiersoflrrk2parkinsonsdisease
AT tolosaeduardo analysisofdnm3andvamp4asgeneticmodifiersoflrrk2parkinsonsdisease
AT ezquerramario analysisofdnm3andvamp4asgeneticmodifiersoflrrk2parkinsonsdisease
AT benromdhansawssan analysisofdnm3andvamp4asgeneticmodifiersoflrrk2parkinsonsdisease
AT benmahdjoubmustapha analysisofdnm3andvamp4asgeneticmodifiersoflrrk2parkinsonsdisease
AT arezkimohamed analysisofdnm3andvamp4asgeneticmodifiersoflrrk2parkinsonsdisease
AT mhirichokri analysisofdnm3andvamp4asgeneticmodifiersoflrrk2parkinsonsdisease
AT hardyjohn analysisofdnm3andvamp4asgeneticmodifiersoflrrk2parkinsonsdisease
AT singletonandrewb analysisofdnm3andvamp4asgeneticmodifiersoflrrk2parkinsonsdisease
AT alcalayroyn analysisofdnm3andvamp4asgeneticmodifiersoflrrk2parkinsonsdisease
AT gasserthomas analysisofdnm3andvamp4asgeneticmodifiersoflrrk2parkinsonsdisease
AT grossetdonaldg analysisofdnm3andvamp4asgeneticmodifiersoflrrk2parkinsonsdisease
AT williamsnigelm analysisofdnm3andvamp4asgeneticmodifiersoflrrk2parkinsonsdisease
AT pittmanalan analysisofdnm3andvamp4asgeneticmodifiersoflrrk2parkinsonsdisease
AT ganorziv analysisofdnm3andvamp4asgeneticmodifiersoflrrk2parkinsonsdisease
AT fernandezsantiagoruben analysisofdnm3andvamp4asgeneticmodifiersoflrrk2parkinsonsdisease
AT bricealexis analysisofdnm3andvamp4asgeneticmodifiersoflrrk2parkinsonsdisease
AT lesagesuzanne analysisofdnm3andvamp4asgeneticmodifiersoflrrk2parkinsonsdisease
AT farrermatthew analysisofdnm3andvamp4asgeneticmodifiersoflrrk2parkinsonsdisease
AT woodnicholas analysisofdnm3andvamp4asgeneticmodifiersoflrrk2parkinsonsdisease
AT morrishuwr analysisofdnm3andvamp4asgeneticmodifiersoflrrk2parkinsonsdisease
AT analysisofdnm3andvamp4asgeneticmodifiersoflrrk2parkinsonsdisease